Nazerian K, Witter R L, Lee L F, Yanagida N
USDA, Agricultural Research Service, East Lansing, Michigan 48823, USA.
Avian Dis. 1996 Apr-Jun;40(2):368-76.
Recombinant fowl poxviruses (rFPV) were constructed to express genes from serotype 1 Marek's disease virus (MDV) coding for glycoproteins B (gB1), C (gC), and D (gD) and tegument proteins UL47 and UL48, as well as genes from serotypes 2 and 3 MDV coding for glycoprotein B (gB2 and gB3). These rFPVs, alone and in various combinations, including combinations of fowl poxvirus (FPV)/gBs with turkey herpesvirus (HVT), were evaluated for ability to protect maternal antibody-positive (ab+) and -negative (ab-) chickens against challenge with highly virulent MDV isolates. The protective efficacy was also compared with that of prototype Marek's disease (MD) vaccines. No protection was induced in ab+ chickens by rFPV expressing gC, gD, UL47, or UL48. In contrast, the rFPV/gB1 construct protected about 23% of ab+ chickens against MDV challenge compared with 26% for cell-associated HVT. Levels of protection by rFPV/gBs of different MDV serotypes was highest for gB1, intermediate for gB2, and lowest for gB3. When rFPV/gB1 was combined with cell-associated HVT, protection was enhanced by an average of 138% compared with the best component monovalent vaccine, and the mean level of protection was 59% compared with 67% for the HVT+SB-1 bivalent vaccine. Relatively high protection (50%) and enhancement (200%) were also observed between rFPV/gB1 and cell-free HVT. These results suggest a specific synergistic interaction between rFPV/gB1 and HVT, possibly analogous to that previously described between serotypes 2 and 3 viruses. Levels of protection by rFPV/ gB1 alone or by bivalent rFPV/gB1+cell-associated HVT were similar to those of conventional cell-associated MD vaccines. However, the bivalent rFPV/gB1+cell-free HVT vaccine was clearly more protective than cell-free HVT alone and, thus, may be the most protective, entirely cell-free MD vaccine thus far described.
构建重组禽痘病毒（rFPV）以表达1型马立克氏病病毒（MDV）编码糖蛋白B（gB1）、C（gC）和D（gD）以及被膜蛋白UL47和UL48的基因，以及2型和3型MDV编码糖蛋白B（gB2和gB3）的基因。对这些rFPV单独以及以各种组合形式，包括禽痘病毒（FPV）/gBs与火鸡疱疹病毒（HVT）的组合，评估其保护母源抗体阳性（ab+）和阴性（ab-）鸡免受高致病性MDV分离株攻击的能力。还将保护效力与原型马立克氏病（MD）疫苗的效力进行了比较。表达gC、gD、UL47或UL48的rFPV未在ab+鸡中诱导出保护作用。相比之下，rFPV/gB1构建体保护了约23%的ab+鸡免受MDV攻击，而细胞结合型HVT的保护率为26%。不同MDV血清型的rFPV/gBs的保护水平以gB1最高，gB2居中，gB3最低。当rFPV/gB1与细胞结合型HVT联合使用时，与最佳的单价疫苗成分相比，保护作用平均提高了138%，平均保护水平为59%，而HVT+SB-1二价疫苗为67%。在rFPV/gB1和无细胞HVT之间也观察到相对较高的保护率（50%）和增强效果（200%）。这些结果表明rFPV/gB1和HVT之间存在特定的协同相互作用，可能类似于先前描述的2型和3型病毒之间的相互作用。单独的rFPV/gB1或二价rFPV/gB1+细胞结合型HVT的保护水平与传统的细胞结合型MD疫苗相似。然而，二价rFPV/gB1+无细胞HVT疫苗明显比单独的无细胞HVT更具保护作用，因此可能是迄今为止描述的最具保护作用的完全无细胞MD疫苗。
